Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human BTN2A1 is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Human DC‑SIGN/CD209 Fc Chimera (Catalog # ) that produces 50% of the optimal binding response is approximately
0.1-0.5 μg/mL.Source
Human embryonic kidney cell, HEK293-derived Gln29-Ala248, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
AnalysisNo results obtained. Gln29 predicted
Predicted Molecular Mass
25 kDa
SDS-PAGE
39-44 kDa, reducing conditions
9058-BT |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
Reconstitution Reconstitute at 100 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Images
Bioactivity
| When Recombinant Human BTN2A1/Butyrophilin 2A1 (Catalog # 9058-BT) is coated at 1 µg/mL, Recombinant Human DC-SIGN/CD209 Fc Chimera (Catalog # 161-DC) binds with a ED50 of 0.1-0.5 μg/mL. |
Background: BTN2A1
Butyrophilin 2A1 (BTN2A1) is an approximately 70 kDa widely expressed and variably glycosylated type I transmembrane glycoprotein (1). Mature human Butyrophilin 2A1 consisits of a 220 amino acid (aa) extracellular domain with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 258 aa cytoplasmic domain (2). Alternative splicing generates additional isoforms of human Butyrophilin 2A1 that lack the first Ig-like domain or transmembrane segment as well as isoforms with substitutions and deletions in the cytoplasmic region. BTN2A1 is widely expressed including on colonic epithelial cells, on immune cells, and in milk fat globules (3, 4). It binds to the C-type lectin DC-SIGN on monocyte-derived dendritic cells, and this interaction can be blocked by soluble gp130 from HIV (3). The polymorphism of BTN2A1 has been associated with metabolic syndrome, type II diabetes mellitus, chronic kidney disease, and hypertension (5, 6).
References:
Arnett, H.A. and J.L. Viney (2014) Nat. Rev. Immunol. 14:559.
Tazi-Ahnini, R. et al. (1997) Immunogenetics 47:55.
Malcherek, G. et al. (2007) J. Immunol. 179:3804.
Cavaletto, M. et al. (2002) Proteomics 2:850.
Oguri, M. et al.(2011) J. Med. Genet. 48:787.
Horibe, H. et al. (2014) Mol. Med. Rep. 9:808.
Long Name:
Butyrophilin Subfamily 2 Member A1
Entrez Gene IDs:
11120 (Human)
Alternate Names:
BK14H9.1; BT2.1; BTF1; BTF1BT2.1butyrophilin BTF1; BTN2A1; butyrophilin subfamily 2 member A1; butyrophilin, subfamily 2, member A1; DJ3E1.1; FLJ36567
